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Abstract
Background:  Clinical profiling of two components for a synthetic peptide-based virosomal malaria
vaccine has yielded promising results, encouraging the search for additional components for inclusion in a
final multi-valent vaccine formulation. This report describes the immunological characterization of linear
and cyclized synthetic peptides comprising amino acids 211-237 of Plasmodium falciparum merozoite
surface protein (MSP-3).
Methods:  These peptides were coupled to phosphatidylethanolamine (PE); the conjugates were
intercalated into immunopotentiating reconstituted influenza virosomes (IRIVs) and then used for
immunizations in mice to evaluate their capacity to elicit P. falciparum cross-reactive antibodies.
Results: While all MSP-3-derived peptides were able to elicit parasite-binding antibodies, stabilization of
turn structures by cyclization had no immune-enhancing effect. Therefore, further pre-clinical profiling was
focused on FB-12, a PE conjugate of the linear peptide. Consistent with the immunological results obtained
in mice, all FB-12 immunized rabbits tested seroconverted and consistently elicited antibodies that
interacted with blood stage parasites. It was observed that a dose of 50 μg was superior to a dose of 10
μg and that influenza pre-existing immunity improved the immunogenicity of FB-12 in rabbits. FB-12
production was successfully up-scaled and the immunogenicity of a vaccine formulation, produced
according to the rules of Good Manufacturing Practice (GMP), was tested in mice and rabbits. All animals
tested developed parasite-binding antibodies. Comparison of ELISA and IFA titers as well as the
characterization of a panel of anti-FB-12 monoclonal antibodies indicated that at least the majority of
antibodies specific for the virosomally formulated synthetic peptide were parasite cross-reactive.
Conclusion: These results reconfirm the suitability of IRIVs as a carrier/adjuvant system for the induction
of strong humoral immune responses against a wide range of synthetic peptide antigens. The virosomal
formulation of the FB-12 peptidomimetic is suitable for use in humans and represents a candidate
component for a virosomal multi-valent malaria subunit vaccine.
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Background
The development of an anti-malarial vaccine represents
one of the most important public health priorities. It is
generally assumed that a multi-stage, multi-component
vaccine is required to provide sufficient protection against
Plasmodium falciparum malaria [1,2]. One approach is the
design of a subunit vaccine that incorporates several syn-
thetic peptide antigens for which there is evidence of pro-
tective immunity from in vitro parasite growth inhibition
assays, experimental malaria infection models and/or
immuno-epidemiological studies. Peptide-based vaccines
could have many advantages compared to conventional
vaccines, such as increased stability and safety and lower
cost [3]. Ideally, synthetic subunit vaccines focus immune
responses on antigenic determinants relevant for protec-
tion, thus avoiding the induction of deleterious immune
responses as observed during P. falciparum infection [4].
However, the development of synthetic peptide vaccines
is often hampered by limited intrinsic immunostimula-
tory properties and the lack of cross-reactivity of elicited
antibodies with native target antigens.
Both problems can be addressed by developing synthetic
peptide structures that induce cross-reactive antibodies
against the parent malaria proteins and by coupling them to
the surface of immunopotentiating reconstituted influenza
virosomes (IRIVs) via a phosphatidylethanolamine (PE)
anchor. IRIVs represent an innovative antigen delivery sys-
tem derived from a mixture of natural and synthetic phos-
pholipids and influenza surface glycoproteins. The
suitability of IRIV as peptide carrier and adjuvant system for
malaria peptidomimetics has been proven in several pre-
clinical [4-10] and clinical [11,12] studies. Experience with
two licensed vaccines based on virosomes has shown that
IRIV based vaccines have an excellent safety profile and are
highly immunogenic also in children and infants [13,14].
One of the target antigens for inclusion into a malaria vac-
cine is the P. falciparum merozoite surface protein (MSP-
3). MSP-3 is a non-integral surface-associated protein that
may be an important target for antibody-mediated protec-
tive immunity, as truncation of the MSP-3 gene reduces
parasite invasion [15]. Antibodies to MSP-3 have shown
parasite growth inhibitory activity in antibody dependent
cellular inhibition (ADCI) assays and in a humanized
SCID mouse P. falciparum infection model [16-20].
Cytophilic antibodies to polymorphic and conserved
epitopes of MSP-3 were shown to be associated with
reduced incidence of malaria in immuno-epidemiological
studies [21-23]. MSP-3 vaccinated Saimiri and Aotus mon-
keys have been partially protected from lethal challenge
with P. falciparum blood stage parasites [24,25].
This report describes the pre-clinical profiling of a viro-
somally-formulated synthetic peptidomimetics compris-
ing amino acids 211-237 of P. falciparum MSP-3.
Methods
Animal studies
All procedures involving living animals were performed in
accordance with the Rules and Regulations for the Protec-
tion of Animal Rights (Tierschutzverordnung) of the Swiss
Bundesamt für Veterinärwesen.
Mouse immunogenicity studies
Peptide synthesis and the preparation of peptide-loaded
virosomes were done as described previously [7,9]. BALB/
c mice were pre-immunized intramuscularly with inacti-
vated influenza virus (1 μg HA per dose [A/Sing]). At least
three weeks later they were immunized with peptide-
loaded IRIVs (containing 5 μg PE-peptide) in intervals of
at least two weeks. Blood was collected before each immu-
nization and two weeks after the final injection.
Rabbit immunogenicity studies
New Zealand rabbits were pre-immunized intramuscu-
larly with inactivated influenza virus (10 μg HA per dose).
Three weeks later they were immunized with peptide-
loaded IRIVs (containing 10, 25 or 50 μg PE-peptide) in
intervals of three weeks. Blood was collected before each
immunization and three weeks after the final injection.
Enzyme-linked immunosorbent assay (ELISA)
Polysorp™ microtiter plates (Nunc, Fisher Scientific, Woh-
len, Switzerland) were coated overnight at 4°C with 100
μL of a 10 μg/mL solution of peptide-PE conjugate in PBS
(pH 7.2). Wells were then blocked with 5% milk powder
in PBS for 30 min at 37°C followed by three washings
with PBS containing 0.05% Tween-20. Plates were then
incubated with serial dilutions of anti-peptide mAbs,
mouse or rabbit sera in PBS containing 0.05% Tween-20
and 0.5% milk powder for 2 h at 37°C. After washing,
plates were incubated with alkaline phosphatase-conju-
gated goat anti-mouse IgG (γ-chain specific) antibodies
(Sigma, St. Louis, MO) or with phosphatase-conjugated
affinity-pure F(ab')2 fragment goat anti-rabbit IgG heavy-
chain antibodies (KPL, Guildford, UK) for 1 h at 37°C.
Phosphatase substrate (1 mg/mL p-nitrophenyl phos-
phate (Sigma)) in buffer (0.14% Na2CO3, 0.3% NaHCO3,
0.02% MgCl2, pH 9.6) was added and incubated at room
temperature. The optical density (OD) of the reaction
product was recorded after appropriate time at 405 nm
using a microplate reader (Sunrise™, Tecan Trading AG,
Switzerland).
NH4SCN elution ELISA
Avidity ELISA analyses with peptide-PE conjugates were
performed essentially as described before [26]. After coat-
ing and blocking, rabbit serum samples were added in
triplicates at constant dilutions (approx. halfmax titer).
After a wash step, plates were incubated 15 min with
NH4SCN diluted in 0.1 M NaH2PO4 buffer (pH 6) at the
following molarities: 5 M, 4 M, 3 M, 2 M, 1 M, 0.5 M, 0.25Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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M. Control wells were incubated with 0.1 M NaH2PO4
buffer without NH4SCN. After washing, plates were incu-
bated with alkaline phosphatase-conjugated affinity-pure
F(ab')2 fragment goat anti-rabbit IgG heavy-chain anti-
bodies (KPL, Guildford, UK) and developed with phos-
phatase substrate solution. The avidity index corresponds
to the NH4SCN concentration (M) eluting 50% of the
bound antibodies.
Generation of anti-FB-12 monoclonal antibodies (mAbs)
Three days before cell fusion, a BALB/c mouse immunized
with FB-12-PE loaded IRIV received an intravenous
booster injection. From the sacrificed mouse the spleen
was aseptically removed and a spleen cell suspension in
IMDM was mixed with PAI mouse myeloma cells as a
fusion partner. Spleen and myeloma cells in a ratio of 1:1
were centrifuged; having the supernatant discarded, the
pellet was mixed with 1 mL pre-warmed polyethylene gly-
col 1500 sterile solution. After 60 s 10 mL of culture
medium were added. After 10 min cells were suspended in
IMDM containing hypoxanthine, aminopterin, thymi-
dine, and 20% foetal bovine serum and cultured in 96-
well tissue culture plates. Cells secreting FB-12-specific
IgG were identified by ELISA coated with FB-12-PE conju-
gate. From two independent fusions five hybridoma cell
lines producing peptide specific mAbs were identified and
cloned twice by limiting dilution. MAbs were purified
from spent culture supernatant of the hybridoma clones
by protein A affinity chromatography (HiTrap rProtein A
FF, Amersham Biosciences). Purified mAbs were dialyzed
against PBS, aliquoted, and stored at -80°C.
Indirect immunofluorescence assay (IFA)
In vitro cultivated P. falciparum parasites were washed and
mixed with two volumes of a solution containing 4%
paraformaldehyde and 0.1% Triton X-100. Droplets of 40
μL of cell suspension were added to each well of a diag-
nostic microscope slide (Flow Laboratories, Baar, Switzer-
land) and incubated for 30 min at room temperature.
Cells were blocked with blocking solution containing 100
mg/mL fatty acid-free bovine serum albumin in PBS.
Immunostaining was performed by incubating the wells
with 25 μL of an appropriate mAb or serum dilution in
blocking solution in a humid chamber for one hour at
room temperature. After five washes with blocking solu-
tion, 25 μL of 5 μg/mL indocarbocyanine dye-conjugated
affinity-pure F(ab')2 fragment goat anti-mouse IgG heavy-
chain antibodies (Jackson ImmunoResearch Laboratories,
West Grove, Pa.), diluted in blocking solution were added
to the wells and incubated for one hour at room tempera-
ture. Finally, the wells were washed five times, mounted
with ProLong® Gold antifade reagent with DAPI (Invitro-
gen) and covered with a coverslip. Antibody binding and
DNA staining were assessed by fluorescence microscopy.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotting
Parasite lysates were prepared by saponin lysis of P. falci-
parum  infected erythrocytes. Cultured parasites were
washed with RPMI medium. Pelleted infected red blood
cells were lysed by mixing with a large volume (adjusted
to 5% haematocrit) of 0.015% (wt/vol) saponin in PBS
and incubated on ice for 20 min. Finally, the pelleted par-
asites were resuspended in PBS and stored at -80°C until
further use.
A total of 50 μL of parasite lysate was solubilized in an
equal volume of 2× loading buffer (1.7 mL of 0.5 M Tris-
HCl [pH 6.8], 2 mL of glycerol, 4.5 mL of 10% sodium
dodecyl sulfate, 1 mL of β-mercaptoethanol, 0.8 mL of
bromophenol blue [0.3%, wt/vol]) and heated to 95°C
for 10 min. Proteins were separated on an SDS-PAGE
minigel and electrophoretically transferred to a nitrocellu-
lose filter by semidry blotting. Blots were blocked with
PBS containing 5% milk powder and 0.1% Tween 20
overnight at 4°C. The filter was cut into strips and incu-
bated with appropriate dilutions of mAbs or immune
serum in blocking buffer for 2 h at room temperature.
After several washing steps, filter strips were incubated
with goat anti-mouse IgG horseradish peroxidase conju-
gated Ig (Bio-Rad Laboratories, Hercules, CA) or horserad-
ish peroxidase conjugated goat anti-rabbit IgG heavy and
light chain antibodies (Bio-Rad Laboratories, Hercules,
CA) for 1 h. Blots were developed using the ECL system
according to manufacturer's instructions.
In vitro growth inhibition assays
In vitro growth inhibition assays with P. falciparum strain
K1 were conducted essentially as described [7]. Briefly,
synchronous late trophozoites were diluted with fresh red
blood cells to result in 0.5% parasitaemia and mixed with
purified mAb. The final haematocrit in cultures was
adjusted to 0.5%. Each culture was set up in sextuplicate
in 96-well flat-bottomed culture plates. After 96 h, the
plates were centrifuged at 180 × g for 5 min, and the cul-
ture supernatants were discarded. Pelleted erythrocytes
were resuspended in 200 μL of PBS supplemented with 15
μg of hydroethidine fluorescent vital stain (Polysciences
Inc., Warrington, Pa.) per mL and incubated at 37°C for
30 min. The erythrocytes were washed with PBS and ana-
lysed in a FACSscan flow cytometer (Becton Dickinson,
San Jose, Calif.) with CellQuest 3.2.1 fl software. A total
of 30,000 cells per sample were analysed. Percent inhibi-
tion was calculated from the geometric mean parasitae-
mia of sextuplicate test and control wells as 100 ×
[(control - test)/control].
Results
Design and synthesis of peptide-PE conjugates
A series of phosphatidylethanolamine (PE)-peptide con-
jugates comprising amino acids 211-237 of the P. falci-Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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parum vaccine candidate antigen MSP-3 was designed and
synthesized, since previous studies [27-29] indicated that
parasite inhibitory epitopes exists between the conserved
residues 212-257. These peptides were linked via two N-
terminally added glycine residues to PE, incorporated into
IRIV's membrane, presenting the antigen on the surface,
and then used for immunizations. Figure 1 gives an over-
view over all MSP-3 derived peptides and peptide-PE con-
jugates that have been used for pre-clinical profiling in
this study.
In addition to FB-12, a PE conjugate of MSP-3211-237 of P.
falciparum  strain K1 (Figure 1A), identical peptide
sequences flanked by two additional cysteine residues
were synthesized. These conjugates were designated FB-13
(Figure 1B) with both cysteine residues being alkylated
with iodoacetamide and FB-14 (Figure 1C) with both
cysteine residues linked to each other by an internal
disulfide bond. FB-13 was expected to have comparable
immunological properties as FB-12 and was produced as
a control for the evaluation of the effects of cyclization.
Finally, an alternative cyclization strategy was developed
in order to achieve a cysteine-independent cyclization of
MSP-3211-237. The resulting peptidomimetic, designated
FB-16, was cyclized to one large loop by introducing (2S,
4S)-4-aminoproline and linking the peptide C-terminus
to the 4-amino group (Figure 1D).
Immunogenicity of virosomal formulations of MSP-3-
derived synthetic peptide-PE conjugates in mice
BALB/c mice were immunized three times with virosoma-
lly formulated peptide-PE conjugates. Pre-immune sera
and sera taken after the second and third immunization
were analysed for the development of peptide specific IgG
in ELISA and for parasite cross-reactive IgG in IFA with in
vitro cultivated blood stage parasites. Already after two
immunizations all mice immunized with either FB-12,
FB-13, FB-14 or FB-16 produced antibodies that showed
specific reactivity with the respective immunogen in
ELISA (Figure 2A). Moreover, all sera were consistently
cross-reactive with schizonts (Figure 2B). For all peptides,
mean serum antibody titers for the respective immunogen
in ELISA were enhanced by the third immunization. Since
structural stabilization by cyclization of the peptide did
not enhance immunogenicity, further preclinical develop-
ment was focused on the linear peptide FB-12.
Generation and characterization of anti-FB-12 mAbs
For a structural characterization of anti-FB-12 antibody
responses, a panel of anti-FB-12 mAbs was generated. Five
hybridoma clones producing mAbs (designated DV2.2
Structures of the synthetic peptides and peptide-PE conjugates prepared in this study Figure 1
Structures of the synthetic peptides and peptide-PE conjugates prepared in this study.Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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and DV3.1 to DV3.4) were selected using a FB-12 specific
peptide ELISA. DV2.2 and the DV3 series of mAbs were
obtained from independent fusions with spleen cells of
two FB-12 immunized BALB/c mice. All five mAbs bound
to all linear and cyclic peptides that comprised aa 211-237
of MSP-3 (Table 1). In order to map the epitopes of the
anti-FB-12 mAbs in more detail, reactivity with truncated
fragments of FB-12 (Figure 2E) was analysed. While loss
of the C-terminal portion of the MSP-3211-237 sequence in
peptide aa 211-228 (structure FB-I-107) did not affect
mAb binding, none of the mAbs reacted in ELISA with a
N-terminally truncated peptide comprising aa 227-237
(structure FB-II-57).
Differential binding of mAbs was observed when testing
for reactivity with a N-terminally less truncated peptide
comprising aa 222-237 (FB-I-171). While mAbs DV3.1,
DV3.3 and DV3.4 showed reactivity with this peptide,
mAbs DV2.2 and DV3.2 were still negative. All five anti-
FB-12 mAbs cross-reacted with parasite expressed MSP-3,
as demonstrated by IFA. With the exception of mAb
DV3.3, all mAbs were also reactive with the MSP-3 protein
in Western blot analysis with total lysates of P. falciparum
blood stage parasites (Table 1).
In vitro growth inhibition assays with blood stage parasites
were performed to assess a parasite inhibitory effect of the
anti-FB-12 mAbs. In contrast to the growth-inhibitory
mAb DV5 specific for apical membrane antigen 1 [7], no
growth inhibition was found in this test system with any
of the anti-FB-12 mAbs tested (Figure 3). Previous reports
have shown that anti-MSP-3 antibodies have no direct
Immune responses elicited by virosomal formulations of MSP-3211-237 derived peptide-PE conjugates Figure 2
Immune responses elicited by virosomal formulations of MSP-3211-237 derived peptide-PE conjugates. Develop-
ment of anti-peptide-PE IgG responses in peptide ELISA (A). Sown are halfmaximal IgG titers for individual animals and the geo-
metric mean (line) after the second and third vaccination. Cross-reactivity of anti-peptide-PE IgG responses with cultured P. 
falciparum blood-stage parasites (B). Shown are individual IFA endpoint titers after the third immunization, lines representing 
the geometric mean. None of the pre-immune sera was positive in ELISA or IFA.
Table 1: Cross-reactivity of anti FB-12 mAbs with FB-12-derived peptides in ELISA and with P. falciparum blood-stage parasites in IFA 
and Western blotting (WB) analysis.
mAb full length peptides truncated peptides Schizont
FB-12 FB-13 FB-14 FB-16 FB-II-57 FB-I-171 FB-I-107
211-237 211-237 211-237 211-237 227-237 222-237 211-228 IFA WB
DV2.2 (IgG1/k) + + + + --+ ++
DV3.1 (IgG1/l) + + + + -++ ++
DV3.2 (IgG1/l) + + + + --+ ++
DV3.3 (IgG1/l) + + + + -++ +-
DV3.4 (IgG2b/l) + + + + -++ ++Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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effect upon merozoite invasion but can cooperate with
blood monocytes to inhibit P. falciparum in vitro growth
[16,18].
Immunogenicity of peptide FB-12 in rabbits
New Zealand rabbits were immunized with two different
doses of virosomally formulated FB-12 (10 μg, and 50 μg
of peptide-PE conjugate) with or without pre-immuniza-
tion with 10 μg inactivated influenza virus (A/Sing). Con-
sistent with the results obtained from the mouse
immunization experiments all FB-12 immunized rabbits
developed IgG antibodies that interacted both with the
peptide immunogen in ELISA (Figure 4) and blood stage
parasites in IFA. In particular in animals not pre-immu-
nized with A/Sing the dose of 50 μg was superior to the 10
μg dose (Figure 4A and Figure 4B). In contrast to the 10 μg
group (Figure 4A), rabbits receiving the 50 μg dose devel-
oped an anti-FB-12 IgG response already after one immu-
nization (Figure 4B). Booster effects after the second and
third immunization were observed both in the low and
high dose groups with variation in the maximum anti-
body titers. Pre-immunization with A/Sing (Figure 4C and
Figure 4D) improved the immunogenicity of FB-12 in rab-
bits especially for the low dose group. In these primed rab-
bits both vaccine doses induced an anti-peptide IgG
response already after the first immunization but with
higher titers in the 50 μg group. Comparable anti-FB-12
IgG titers were reached after the second immunization in
both A/Sing primed dose-groups and no significant
increase in titers resulted from the third immunization.
Immunogenicity of a virosomal formulation of a FB-12 
produced according to the rules of GMP
As a next step, synthesis of FB-12 was up-scaled and the
immunogenicity of a batch produced according to the
rules of GMP was tested. A/Sing primed BALB/c mice were
immunized twice with 5 μg of virosomally formulated FB-
12. Already one immunization elicited detectable titers of
anti-FB-12 IgG in peptide ELISA and a second immuniza-
tion led to a strong titer increase (Figure 5A). All FB-12
immunized mice developed high IFA IgG antibody titers
(Figure 5C) and the observed fluorescence staining pat-
tern was typical for a merozoite surface staining (Figure
6A). All anti-FB-12 immune sera were consistently cross-
reactive with MSP-3 expressed by blood stage schizonts as
detected in Western blot analysis with parasite lysate (Fig-
ure 5E). The observed triple band staining pattern is char-
acteristic for the processed MSP-3 protein [30].
Pre-clinical profiling was continued by immunogenicity
studies in a second species, namely rabbits. Already one
immunization of A/Sing primed New Zealand rabbits
with 25 μg of FB-12-loaded IRIV elicited high titers of anti-
FB-12 IgG in ELISA (Figure 5B) and schizont cross-reactive
IgG in IFA (Figure 5D and Figure 6B). While a second
immunization led to a strong ELISA and IFA titer increase,
a third immunization had no further booster effect. The
mean avidity index, a measure for antibody affinity matu-
ration, of the FB-12-induced IgG response in rabbits
increased slightly after the third immunization (Figure
5F).
Discussion
Previously, an iterative optimization process was used to
develop synthetic peptides mimicking the native structure
of surface loops of leading P. falciparum vaccine candidate
antigens [7-10,31]. Furthermore, a technology was devel-
oped for the delivery of PE-coupled synthetic peptide anti-
gens on the surface of influenza virosomes (IRIVs). A
phase I clinical trial demonstrated safety and parasite
cross-reactive immunogenicity of two IRIV-formulated
peptides derived from the circumsporozoite surface pro-
tein (CSP) and the apical membrane antigen 1 (AMA1)
[11]. Purified immunoglobulins from CSP immunized
volunteers inhibited substantially sporozoite migration
and invasion of hepatocytes in vitro [4]. Combined deliv-
ery of the two virosomal constructs did not interfere with
immunogenicity of either peptide, demonstrating the
suitability of the IRIV system for development of multi-
valent subunit vaccines. In a phase IIa trial the two com-
bined IRIV-formulated peptides showed evidence of vac-
cine-induced blood-stage efficacy for the first time in a
sporozoite challenge study [12]. The malaria naive study
participants were not completely protected from malaria,
but lower rates of parasite growth and the presence of
morphologically abnormal parasites (crisis forms) were
In vitro growth inhibition assay Figure 3
In vitro growth inhibition assay. Blood stage parasites 
were synchronized and cultured in sextuplicate in the pres-
ence of mAbs or equal volumes of PBS as control. Numbers 
of parasites were determined by FACS after two blood stage 
cycles and inhibition calculated relative to the PBS control. 
Shown are the means ± S.D. of two experiments. The 
growth-inhibitory mAb DV5, specific for apical membrane 
antigen 1, was used a positive control [7].Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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significantly observed in vaccinated volunteers. While
these clinical trials support the concept of using peptide-
loaded IRIVs for vaccination in humans, it is assumed that
additional key P. falciparum antigens need to be added to
produce an effective multi-valent malaria vaccine. In the
case of MSP-3, choice of the sequence stretch incorporated
was guided by structural considerations and pre-existing
knowledge on epitopes of parasite inhibitory antibodies
[18,19,27-29].
In this study, immunogenicity of a small library of linear
and constrained MSP-3-derived peptides was compared.
In particular, it was investigated, whether stabilization of
turn structures by cyclization improves the ability of the
peptides to elicit antibodies that cross-react with the
native target protein. Suitability of the linear peptide indi-
cates that intramolecular interactions lead to a correct
folding of the linear FB-12 peptide and that anchoring to
the surface of IRIVs has no deleterious effects on this proc-
ess. In contrast, delivery of peptide antigens adsorbed to
alum or other adjuvants, may disturb the structure even of
conformationally restricted peptides [6].
Since FB-12 was also the easiest structure to synthesize,
further development was focused on this peptide-PE con-
jugate as a new candidate for incorporation into a viro-
somal multi-valent subunit malaria vaccine. Virosomally
formulated FB-12 elicited high titers of blood stage para-
site cross-reactive antibodies both in all inbred mice and
in all rabbits with diverse immunogenetic backgrounds
tested.
In order to test whether a pre-existing immunity against
the virosomal carrier system influences its efficacy, ani-
mals were immunized with influenza antigens prior to
immunization with the virosomal malaria vaccine candi-
Development of anti-peptide IgG responses in ELISA after immunization with IRIV-formulated FB-12 in rabbits Figure 4
Development of anti-peptide IgG responses in ELISA after immunization with IRIV-formulated FB-12 in rab-
bits. Groups of three animals were immunized with two different doses (10 μg [A, C], and 50 μg [B, D] peptide-PE conjugate) 
without (A, B) or with (C, D) pre-immunization with 10 μg inactivated influenza virus (A/Sing). Shown are serial dilutions 
(means +/-SD) of rabbit sera taken two weeks after first, second and third immunization. No peptide-specific IgG responses 
were found in pre-immune sera.Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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date antigens. These experiments have shown that influ-
enza pre-immunity enhances immune responses against
the malaria antigen. Possible explanations are (i) opsoni-
zation of IRIVs with pre-existing anti-influenza antibod-
ies, leading to enhanced uptake by antigen presenting
cells and (ii) activation of influenza-specific memory T
cells, providing T cell help to FB-12 specific B cells. The
effect was most pronounced after the first immunization
and leveled of afterwards, presumably because anti-influ-
enza immune responses are induced by the first immuni-
zation with antigen-loaded virosomes. These results show
that pre-immunity to the virosomal antigen delivery sys-
tem enhances the immune response but is not a pre-req-
uisite.
Influenza specific immune responses have been found in
African and Asian children [32-34] and experience with
two licensed vaccines based on virosomes have shown
that the technology is suitable for use in children and
infants [13,14].
Production of sets of mAbs against a peptide antigen is
instrumental for evaluating the quality of vaccine candi-
dates [6,10]. One key criterion is the proportion of para-
site binding mAbs within the population of peptide
reactive antibodies elicited. In the case of FB-12 all five
generated anti-FB-12 mAbs derived from two mice bound
to blood stage parasites. Evidence for diversity of the fine
specificity of the mAbs came from the analysis of their
cross-reactivity with partial fragments of FB-12. Results
indicate that for all mAbs the most essential amino acids
for recognition are covered by the N-terminal portion of
FB-12 (aa 211-228) and that mAbs DV3.1, DV3.3 and
DV3.4 seem to interact primarily with aa 222-228.
Analyses of the IgG subclass profiles of the induced FB-12-
specific mAbs showed a predominance of the IgG1 iso-
type. Despite binding to the blood stage parasites, the
anti-FB-12 mAbs had no effect on parasite replication in
vitro. It has been reported previously that anti-MSP-3
inhibitory effects involve monocytes in a process called
antibody-dependent cellular inhibition (ADCI) [16,18]. It
would therefore be interesting to test our mAbs in an
ADCI test system. However, the correlation of in vitro
Immunogenicity of a virosomal FB-12 formulation produced  according to the rules of GMP Figure 5
Immunogenicity of a virosomal FB-12 formulation 
produced according to the rules of GMP. Development 
of anti-peptide IgG responses in mice (A) and in rabbits (B). 
Shown are serial dilutions of sera in peptide-ELISA (means +/
-SD). Cross-reactivity of anti-FB-12 IgG responses of mice 
(C) and rabbits (D) with cultured P. falciparum blood-stage 
parasites in IFA. E: Western-blot analysis of mouse serum 
samples with blood stage parasite lysate. Pooled pre-immune 
serum (E, lane 1) and individual serum samples (E, lanes 2-6) 
collected two weeks after the second immunization were 
used at a dilution of 1:10'000. F: Mean avidity indices for anti-
FB-12 IgG responses of rabbits three weeks after the first, 
second and third immunization. The avidity index corre-
sponds to the NH4SCN concentration (M) where 50% of the 
bound antibodies are eluted. Shown are means +/-SD. Wil-
coxon signed-rank test was used to calculate the statistical 
significance of a difference in avidity between the third and 
the first vaccination.
Development of MSP-3 cross-reactive IgG in IFA with P. falci- parum schizonts upon immunization with FB-12-PE loaded  IRIV produced according to the rules of GMP Figure 6
Development of MSP-3 cross-reactive IgG in IFA 
with P. falciparum schizonts upon immunization with 
FB-12-PE loaded IRIV produced according to the 
rules of GMP. Immune sera of mice (A) and rabbits (B) 
taken three weeks after the second immunization were 
tested for parasite binding. Sera were diluted 1:1000 and rep-
resentative examples are shown. The left panel shows DNA 
staining with DAPI (blue), the middle panel Cy3-immunofluo-
rescence staining (red), the right picture is the merge.Malaria Journal 2009, 8:314 http://www.malariajournal.com/content/8/1/314
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growth inhibitory activities of antibodies with their
potential protective capacity in vivo is incompletely under-
stood.
Production of FB-12 was successfully up-scaled and a for-
mulation produced according to the rules of GMP was
immunogenic, leading to seroconversion in all immu-
nized mice and rabbits. IFA titers in mice and rabbits
closely followed ELISA titers, indicating a close relation-
ship between FB-12 and the natural conformation of
MSP-3. In an attempt to gain evidence for affinity matura-
tion of FB-12 specific B cells upon repeated immunization
of rabbits with FB-12, binding inhibition ELISAs with cha-
otropic salt were performed to measure avidity of peptide-
specific IgG. Affinity maturation, indicative for memory B
cell formation, was evidenced by a slight increase in anti-
FB-12 antibody avidity over the course of immunization.
In contrast to mice and humans, in rabbits immunoglob-
ulin genes diversify by both somatic hypermutation and
somatic gene conversion during the course of a T cell-
dependent immune response [35].
Conclusion
Taken together, it was possible to induce parasite cross-
reactive antibodies with a human compatible formulation
of a synthetic MSP-3-derived peptide in mice and rabbits.
Clinical grade material has been produced and is available
for phase I clinical testing.
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